Molecular imaging plays an important role in detection and staging of hematologic malignancies. Multiple myeloma (MM) is an age-related hematologic malignancy of clonal bone marrow plasma cells characterized by destructive bone lesions and is fatal in most patients. Traditional skeletal survey and bone scans have sensitivity limitations for osteolytic lesions manifested in MM. Progressive biomedical imaging technologies such as low-dose CT, molecularly targeted PET, MRI, and the functional-anatomic hybrid versions (PET/CT and PET/MRI) provide incremental advancements in imaging MM. Imaging with PET and MRI using molecularly targeted probes is a promising precision medicine platform that might successfully address the clinical ambiguities of myeloma spectrum diseases. The intent of this focus article is to provide a concise review of the present status and promising developments on the horizon, such as the new molecular imaging biomarkers under investigation that can either complement or potentially supersede existing standards.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalJournal of Nuclear Medicine
Issue number1
StatePublished - Jan 1 2016


  • Metabolic imaging
  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Multiple myeloma (MM)
  • PET/CT
  • Receptor very late antigen-4 (VLA-4)


Dive into the research topics of 'New approaches to molecular imaging of multiple myeloma'. Together they form a unique fingerprint.

Cite this